# US 2006/0041170 A1 · Synthesis of triethylenetetramines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0041170 A1
- Document ID: US20060041170A1
- Status: Published application
- Kind: A1
- Application number: 11/184,761
- Filed: 2005-07-19
- Published: 2006-02-23
- Earliest claimed: 2004-07-19
- Assignees: Protemix Corporation Limited
- Inventors: Marco Jonas; Irene Vaulont; Antonio Soi; Gunther Schmidt
- Web page: https://patentgrep.com/patent/US20060041170A1

## CPC

- C07D 233/02: having no double bonds between ring members or between ring members and non-ring members
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 39/04: Chelating agents
- C07C 55/10: Succinic acid
- C07C 57/145: Maleic acid
- C07C 57/15: Fumaric acid
- C07C 209/48: by reduction of nitriles
- C07C 209/62: by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds (C07C209/24 takes precedence)
- C07C 209/76: by nitration
- C07C 211/10: Diaminoethanes
- C07C 211/13: Amines containing three or more amino groups bound to the carbon skeleton
- C07C 211/14: Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
- C07C 255/30: containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
- C07D 233/26: Radicals substituted by carbon atoms having three bonds to hetero atoms
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

## Claims

### Claim 1

A process for preparing triethylenetetramines or triethylenetetramine salts, comprising hydrolyzing in the presence of an acid a compound selected from the group consisting of 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine, (2-amino-ethyl)-{2-[(2-amino-ethyl)-tert-butoxycarbonyl-amino]-ethyl}-carbamic acid tert-butyl ester, and benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine.

### Claim 2 (depends on 1)

The process of claim 1, wherein said 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine is prepared by reducing (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile.

### Claim 3 (depends on 1)

The process of claim 1, wherein said 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine is prepared by
(a) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with benzaldehyde to prepare (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile; and
(b) reducing said (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile.

### Claim 4 (depends on 3)

The process of claim 3, comprising purifying said (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile.

### Claim 5 (depends on 1)

The process of claim 1, wherein said 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine is prepared by
(a) alkylating ethylenediamine by reacting ethylenediamine with i. formaldehyde, a cyanide salt, and an acid; or
ii. a haloacetonitrile and a base;
to prepare [2-(cyanomethyl-amino)-ethylamino]-acetonitrile;
(b) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with benzaldehyde to prepare (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile; and
(c) reducing said (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile.

### Claim 6 (depends on 1)

The process of claim 1, wherein said (2-amino-ethyl)-{2-[(2-amino-ethyl)-tert-butoxycarbonyl-amino]-ethyl}-carbamic acid tert-butyl ester is prepared by reducing [2-(tert-butoxycarbonyl-cyanomethyl-amino)-ethyl]-cyanomethyl-carbamic acid tert-butyl ester.

### Claim 7 (depends on 1)

The process of claim 1, wherein said (2-amino-ethyl)-{2-[(2-amino-ethyl)-tert-butoxycarbonyl-amino]-ethyl}-carbamic acid tert-butyl ester is prepared by
(a) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with Boc2O to prepare [2-(tert-butoxycarbonyl-cyanomethyl-amino)-ethyl]-cyanomethyl-carbamic acid tert-butyl ester; and
(b) reducing said [2-(tert-butoxycarbonyl-cyanomethyl-amino)-ethyl]-cyanomethyl-carbamic acid tert-butyl ester.

### Claim 8 (depends on 7)

The process of claim 7, comprising purifying said [2-(tert-butoxycarbonyl-cyanomethyl-amino)-ethyl]-cyanomethyl-carbamic acid tert-butyl ester.

### Claim 9 (depends on 1)

The process of claim 1, wherein said (2-amino-ethyl)-{2-[(2-amino-ethyl)-tert-butoxycarbonyl-amino]-ethyl}-carbamic acid tert-butyl ester is prepared by
(a) alkylating ethylenediamine by reacting ethylenediamine with
i. formaldehyde, a cyanide salt, and an acid; or
ii. a haloacetonitrile and a base;
to prepare [2-(cyanomethyl-amino)-ethylamino]-acetonitrile;
(b) reacting said [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with Boc2O to prepare [2-(tert-butoxycarbonyl-cyanomethyl-amino)-ethyl]-cyanomethyl-carbamic acid tert-butyl ester; and
(c) reducing said [2-(tert-butoxycarbonyl-cyanomethyl-amino)-ethyl]-cyanomethyl-carbamic acid tert-butyl ester.

### Claim 10 (depends on 1)

The process of claim 1, wherein said benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine is prepared by reacting triethylenetetramine with benzaldehyde.

### Claim 11 (depends on 10)

The process of claim 10, further comprising purifying said benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine.

### Claim 12 (depends on 1)

The process of claim 1, wherein said benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine is prepared by reacting 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine with benzaldehyde.

### Claim 13 (depends on 1)

The process of claim 1, wherein said benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine is prepared by
(a) reducing (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile to form 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine; and
(b) reacting said 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine with benzaldehyde.

### Claim 14 (depends on 2, 3, 5, 6, 7, 13)

The process of claims 2, 3, 5, 6, 7 or 13, wherein the reduction is conducted by reaction with LiAlH3OMe.

### Claim 15 (depends on 1)

The process of claim 1, wherein said benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine is prepared by
(a) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with benzaldehyde to produce (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile;
(b) reducing said (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile to form 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine; and
(c) reacting said 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine with benzaldehyde.

### Claim 16 (depends on 15)

The process of claim 15, comprising purifying said (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile.

### Claim 17 (depends on 1)

The process of claim 1, wherein said benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine is prepared by
(a) alkylating ethylenediamine by reacting ethylenediamine with
i. formaldehyde, a cyanide salt, and an acid; or
ii. a haloacetonitrile and a base;
to prepare [2-(cyanomethyl-amino)-ethylamino]-acetonitrile;
(b) reacting said [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with benzaldehyde to prepare (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile;
(c) reducing said (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile to form 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine; and
(d) reacting said 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine with benzaldehyde.

### Claim 18 (depends on 1)

The process of claim 1, wherein said acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propanoic acid, hydroxyacetic acid, pyruvic acid, oxalic acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-sulfonic acid, cyclamic acid, tartaric acid, succinic acid, malic acid, lactic acid, citric acid, maleic acid, salicyclic acid, p-aminosalicyclic acid, pamoic acid, and fumaric acid.

### Claim 19 (depends on 18)

The process of claim 18, wherein said acid is succinic acid, and wherein said hydrolysis produces triethylenetetramine disuccinate.

### Claim 20 (depends on 18)

The process of claim 18, wherein said acid is hydrochloric acid, and wherein said hydrolysis produces triethylenetetramine tetrahydrochloride.

### Claim 21

A process for preparing triethylenetetramine dihydrochloride, comprising:
(a) reacting triethylenetetramine tetrahydrochloride with a base in a solvent to produce triethylenetetramine and hydrochloride salt;
(b) removing said hydrochloride salt from solution;
(c) reacting said triethylenetetramine with about 2 equivalents of concentrated hydrochloric acid to form triethylenetetramine dihydrochloride; and
(d) adding an alcohol to the solution and precipitating said triethylenetetramine dihydrochloride.

### Claim 22

A process for preparing triethylenetetramine or a salt thereof, comprising hydrolyzing in the presence of an acid a compound selected from the group consisting of compounds of formula (I), formula (II), and formula (III)
wherein R is an amino protecting group, and wherein R1, R2, R3, R4, R5, and R6 may be the same or different, and may be hydrogen, an alkyl group including from one to twelve carbon atoms, an aryl group, or an aromatic alkyl group.

### Claim 23 (depends on 22)

The process of claim 22, wherein said compound of formula (I) is prepared by reducing a compound of formula (IV)

### Claim 24 (depends on 22)

The process of claim 22, wherein said compound of formula (I) is prepared by
(a) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with an imidazolidine-forming amine protecting group reagent to prepare a compound of formula (IV); and
(b) reducing said compound of formula (IV).

### Claim 25 (depends on 22)

The process of claim 22, wherein said compound of formula (I) is prepared by:
(a) alkylating ethylenediamine by reacting ethylenediamine with
i. formaldehyde, a cyanide salt, and an acid; or
ii. a haloacetonitrile and a base;
to prepare [2-(cyanomethyl-amino)-ethylamino]-acetonitrile;
(b) reacting said [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with an imidazolidine-forming amine protecting group reagent to prepare a compound of formula (IV); and
(c) reducing said compound of formula (IV).

### Claim 26 (depends on 22)

The process of claim 22, wherein said compound of formula (II) is prepared by reduction of a compound of formula (VI)

### Claim 27 (depends on 22)

The process of claim 22, wherein said compound of formula (II) is prepared by
(a) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with an amine protecting group reagent to prepare a compound of formula (VI); and
(b) reducing said compound of formula (VI).

### Claim 28 (depends on 22)

The process of claim 22, wherein said compound of formula (II) is prepared by
(a) alkylating ethylenediamine by reacting ethylenediamine with
i. formaldehyde, a cyanide salt, and an acid; or
ii. a haloacetonitrile and a base
to prepare [2-(cyanomethyl-amino)-ethylamino]-acetonitrile;
(b) reacting said [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with an amine protecting group reagent to prepare a compound of formula (VI); and
(c) reducing said compound of formula (VI).

### Claim 29 (depends on 22)

The process of claim 22, wherein said compound of formula (III) is prepared by reacting triethylenetetramine or a salt thereof with an imidazolidine-forming amine protecting group reagent.

### Claim 30 (depends on 22)

The process of claim 22, wherein said compound of formula (III) is prepared by reacting a compound of formula (I) with an imidazolidine-forming amine protecting group reagent.

### Claim 31 (depends on 22)

The process of claim 22, wherein said compound of formula (III) is prepared by
(a) reducing a compound of formula (IV) to form a compound of formula (I); and
(b) reacting said compound of formula (I) with an imidazolidine-forming amine protecting group reagent.

### Claim 32 (depends on 22)

The process of claim 22, wherein said compound of formula (III) is prepared by
(a) reacting [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with an imidazolidine-forming amine protecting group to form a compound of formula (IV);
(b) reducing said compound of formula (IV) to form a compound of formula (I); and
(c) reacting said compound of formula (I) with an imidazolidine-forming amine protecting group reagent.

### Claim 33 (depends on 22)

The process of claim 22, wherein said compound of formula (III) is prepared by
(a) alkylating ethylenediamine by reacting ethylenediamine with
i. formaldehyde, a cyanide salt, and an acid; or
ii. a haloacetonitrile and a base
to prepare [2-(cyanomethyl-amino)-ethylamino]-acetonitrile;
(b) reacting said [2-(cyanomethyl-amino)-ethylamino]-acetonitrile with an imidazolidine-forming amine protecting group to form a compound of formula (IV);
(c) reducing said compound of formula (IV) to form a compound of formula (I); and
(d) reacting said compound of formula (I) with an imidazolidine-forming amine protecting group reagent.

### Claim 34 (depends on 22)

The process of claim 22, wherein said acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propanoic acid, hydroxyacetic acid, pyruvic acid, oxalic acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-sulfonic acid, cyclamic acid, tartaric acid, succinic acid, malic acid, lactic acid, citric acid, maleic acid, salicyclic acid, p-aminosalicyclic acid, pamoic acid, and fumaric acid.

### Claim 35

2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine.

### Claim 36

The use of 2-[3-(2-amino-ethyl)-2-phenyl-imidazolidin-1-yl]-ethylamine as an intermediate in the synthesis of triethylenetetramine and salts thereof.

### Claim 37

(3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile.

### Claim 38

The use of (3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetonitrile as an intermediate in the synthesis of triethylenetetramine and salts thereof.

### Claim 39

2-(3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetamide.

### Claim 40

The use of 2-(3-cyanomethyl-2-phenyl-imidazolidin-1-yl)-acetamide as an intermediate in the synthesis of triethylenetetramine and salts thereof.

### Claim 41

2-(3-carbamoylmethyl-2-phenyl-imidazolidin-1-yl)-acetamide.

### Claim 42

The use of 2-(3-carbamoylmethyl-2-phenyl-imidazolidin-1-yl)-acetamide as an intermediate in synthesis of triethylenetetramine and salts thereof.

### Claim 43

Benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine.

### Claim 44

The use of benzylidene-(2-{3-[2-(benzylidene-amino)-ethyl]-2-phenyl-imidazolidin-1-yl}-ethyl)-amine as an intermediate in the synthesis of triethylenetetramine and salts thereof.

### Claim 45

A polymorph of triethylenetetramine disuccinate, wherein said polymorph has a DSC extrapolated onset/peak melting temperature of from between about 170° C. to about 190° C.

### Claim 46 (depends on 45)

A polymorph of claim 45 wherein said DSC extrapolated onset/peak melting temperature is 180.05/179.91° C.

### Claim 47 (depends on 45)

The polymorph of claim 45, wherein said polymorph has infrared peaks at wavenumbers at 3148, 1645, 1549, 1529, 1370, 1271, 1172, 1152, and 1033.

### Claim 48

A Form I polymorph of triethylenetetramine dihydrochloride, wherein said Form I polymorph is characterized by a DSC extrapolated onset/peak melting temperature of between about 111° C. to 132° C.

### Claim 49 (depends on 47)

A polymorph of claim 47 wherein said DSC extrapolated onset/peak melting temperature is 121.96/122.78° C.

### Claim 50 (depends on 48)

The Form I polymorph of claim 48, wherein said Form I polymorph is characterized by infrared peaks at wavenumbers 1043, 1116, 1300, 1328, 1557, 2833, 2895, 2902, and 3216.

### Claim 51

A Form II polymorph of triethylenetetramine dihydrochloride, wherein said Form II polymorph is characterized by a DSC extrapolated onset/peak melting temperature of from between about 106° C. to about 126° C.

### Claim 52 (depends on 50)

A polymorph of claim 50 wherein said DSC extrapolated onset/peak melting temperature is 116.16/116.76° C.

### Claim 53 (depends on 51)

The Form II polymorph of claim 51, wherein said Form II polymorph is characterized by infrared peaks at wave numbers 1039, 1116, 1352, 1519, 2954, 2986, 3276, and 3298.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A pharmaceutical composition comprising substantially pure triethylenetetramine disuccinate made in accordance with the process as defined in any one of claims 1 to 20 or 22 to 34.

### Claim 55

A pharmaceutical composition comprising substantially pure triethylenetetramine disuccinate.

### Claim 56

A pharmaceutical composition comprising substantially pure triethylenetetramine disuccinate and a pharmaceutically acceptable excipient.

### Claim 57

Reduction of a nitrile by reacting a nitrile with LiAlH3OMe

### Claim 58

A substantially pure triethylenetetramine disuccinate.

### Claim 59

An isolated triethylenetetramine disuccinate salt that has a purity range selected from the group consisting of 50%, 55%, 60% pure, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% pure.

### Claim 60

Substantially pure triethylenetetraminedisuccinate anhydrate.

### Claim 61

Substantially pure triethylenetetramine tetramaleate dihydrate.

### Claim 62

Substantially pure triethylenetetramine tetrafumarate tetrahydrate.

### Claim 63

A composition comprising a substantially pure triethylenetetramine disuccinate crystal having alternating layers of triethylenetetramine molecules and succinate molecules.

### Claim 64 (depends on 63)

A composition of claim 63 wherein the triethylenetetramine disuccinate is triethylenetetramine disuccinate anhydrate.

### Claim 65

A composition comprising a substantially pure triethylenetetramine maleate dihydrate crystal having alternating layers of triethylenetetramine molecules and maleate molecules 66. A composition comprising a substantially pure triethylenetetramine fumarate tetrahydrate crystal having alternating layers of triethylenetetramine molecules and fumarate molecules.

### Claim 67

A crystal of a triethylenetetramine disuccinate having the structure defined by the co-ordinates of Table 3B.

### Claim 68

A crystal of a triethylenetetramine disuccinate having the structure defined by the co-ordinates of Table 3C.

### Claim 69

A crystal of a triethylenetetramine maleate dihydrate having the structure defined by the co-ordinates of Table 4B.

### Claim 70

A crystal of a triethylenetetramine maleate dihydrate having the structure defined by the co-ordinates of Table 4C.

### Claim 71

A crystal of a triethylenetetramine fumarate tetrahydrate having the structure defined by the co-ordinates of Table 5B.

### Claim 72

A crystal of a triethylenetetramine fumarate tetrahydrate having the structure defined by the co-ordinates of Table 5C.

### Claim 73 (depends on 60, 61, 62)

A pharmaceutical composition comprising a compound according to any of claims 60, 61 or 62 and a pharmaceutically acceptable carrier.

### Claim 74 (depends on 63, 65, 66)

A pharmaceutical composition comprising a triethylenetetramine crystal in substantially the form according to any of claims 63, 65 or 66 and a pharmaceutically acceptable carrier.

### Claim 75 (depends on 67, 68, 69, 70, 71, 72)

A pharmaceutical composition comprising a triethylenetetramine crystal in substantially the form according to any of claims 67-71 or 72 and a pharmaceutically acceptable carrier.
